<DOC>
	<DOCNO>NCT02045160</DOCNO>
	<brief_summary>In study , aim investigate incidence adverse reaction , effectiveness gene polymorphism associate plasma level sulfamethoxazole-trimethoprim metabolite ( include N4-acetyl-sulfamethoxazole , sulfamethoxazole hydroxylamine sulfamethoxazole-nitroso ) . And also aim investigate factor associate sulfamethoxazole-trimethoprim induced acute psychosis .</brief_summary>
	<brief_title>A Pharmacokinetic Pharmacogenetic Study Patients Receiving Sulfamethoxazole-trimethoprim Therapy</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>male female age 20 year old use oral intravenous form sulfamethoxazoletrimethoprim patient 20 year age</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>